F. Barlesi, J. Mazieres, J. Merlio, D. Debieuvre, J. Mosser et al., Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT), Lancet. 2 avr, vol.387, pp.1415-1441, 2016.

F. Barlesi, D. Debieuvre, V. Westeel, H. Léna, R. Veillon et al., Biomarqueurs France : résultats à long terme du profilage moléculaire en routine des cancers bronchiques non à petites cellules, Abstr Mal Respir. janv, vol.36, pp.38-47, 2019.

A. Choughule, V. Noronha, A. Joshi, S. Desai, N. Jambhekar et al., Epidermal growth factor receptor mutation subtypes and geographical distribution among Indian non-small cell lung cancer patients, Indian J Cancer. juin, vol.50, issue.2, pp.107-118, 2013.

Y. Shi, J. Au, S. Thongprasert, S. Srinivasan, C. Tsai et al., Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER), J Thorac Oncol. févr, vol.9, issue.2, pp.154-62, 2014.

M. P. Rivera, A. C. Mehta, and M. M. Wahidi, Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, Chest. mai, vol.143, issue.5, pp.142-165, 2013.

W. D. Travis, E. Brambilla, A. G. Nicholson, Y. Yatabe, J. Austin et al., The 2015 World Health Organization Classification of Lung Tumors, J Thorac Oncol. sept, vol.10, issue.9, pp.1243-60, 2015.

W. D. Travis, E. Brambilla, M. Noguchi, A. G. Nicholson, K. R. Geisinger et al., International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma, J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. févr, vol.6, issue.2, pp.244-85, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00561753

, Délais de prise en charge des quatre cancers les plus fréquents dans plusieurs régions de France en 2011 et 2012 : sein, poumon, côlon, prostate

P. Goldstraw, K. Chansky, J. Crowley, R. Rami-porta, H. Asamura et al., The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer, J Thorac Oncol. janv, vol.11, issue.1, pp.39-51, 2016.

R. Rami-porta, V. Bolejack, D. Giroux, K. Chansky, and J. Crowley, The IASLC Lung Cancer Staging Project: The New Database to Inform the Eighth Edition of the TNM Classification of Lung Cancer, J Thorac Oncol, vol.9, issue.11, pp.1618-1642, 2014.

W. Eberhardt, A. Mitchell, J. Crowley, H. Kondo, Y. T. Kim et al., The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer, J Thorac Oncol Off Publ Int Assoc Study Lung Cancer, vol.10, issue.11, pp.1515-1537, 2015.

W. D. Travis, T. V. Colby, B. Corrin, Y. Shimosato, E. Brambilla et al., Histological typing of lung and pleural tumours, 1999.

S. Couraud, V. Westeel, A. C. Toffart, and P. J. Souquet, et le comité de rédaction des référentiels Auvergne Rhône-Alpes en oncologie thoracique. Référentiel sur le cancer bronchique non à petites-cellules : actualisation 2019. ARISTOT, 2019.

E. Brambilla and S. Lantuejoul, Nouvelle classification des cancers pulmonaires : application aux prélèvements biopsiques de petite taille, Ann Pathol, vol.30, issue.5, pp.60-63, 2010.

J. Yokota and T. Kohno, Molecular footprints of human lung cancer progression, Cancer Sci, vol.95, issue.3, pp.197-204, 2004.

D. Hanahan and R. A. Weinberg, Hallmarks of Cancer: The Next Generation. Cell. 4 mars, vol.144, pp.646-74, 2011.

M. S. Lawrence, P. Stojanov, P. Polak, G. V. Kryukov, K. Cibulskis et al., Mutational heterogeneity in cancer and the search for new cancer genes, Nature. 11 juill, vol.499, issue.7457, pp.214-222, 2013.

T. J. Lynch, D. W. Bell, R. Sordella, S. Gurubhagavatula, R. A. Okimoto et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N Engl J Med. 20 mai, vol.350, issue.21, pp.2129-2168, 2004.

A. T. Shaw, D. Kim, K. Nakagawa, T. Seto, L. Crinó et al., Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N Engl J Med. 20 juin, vol.368, issue.25, pp.2385-94, 2013.

T. Li, H. Kung, P. Mack, and . Gandara, Genotyping and Genomic Profiling of Non-Small-Cell Lung Cancer: Implications for Current and Future Therapies, J Clin Oncol. 10 mars, vol.31, issue.8, pp.1039-1088, 2013.

, Synthèse de l'activité des plateformes hospitalières de génétique moléculaire des cancers en 2012, en vue d'optimiser leur évolution, janv, 2014.

S. P. Nana-sinkam and C. A. Powell, American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest. mai, vol.143, issue.5, pp.30-39, 2013.

F. Sanger, S. Nicklen, and A. R. Coulson, DNA sequencing with chain-terminating inhibitors, Proc Natl Acad Sci U S A. déc, vol.74, issue.12, pp.5463-5470, 1977.

, Plateformes hospitalières de génétique moléculaire des cancers

A. Mcleer-florin, D. Moro-sibilot, A. Melis, D. Salameire, C. Lefebvre et al., Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study, J Thorac Oncol. 1 févr, vol.7, issue.2, pp.348-54, 2012.

J. Mendelsohn and J. Baselga, Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer, J Clin Oncol. 21 sept, 2016.

A. Citri, K. B. Skaria, and Y. Yarden, The deaf and the dumb: the biology of ErbB-2 and ErbB-3, Exp Cell Res. 10 mars, vol.284, issue.1, pp.54-65, 2003.

J. Schlessinger, Ligand-Induced, Receptor-Mediated Dimerization and Activation of EGF Receptor, Cell. 20 sept, vol.110, issue.6, pp.669-72, 2002.

R. J. Shaw, L. C. Cantley, and . Ras, PI(3)K and mTOR signalling controls tumour cell growth, Nature. 25 mai, vol.441, issue.7092, pp.424-454, 2006.

W. Pao and V. A. Miller, Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non-Small-Cell Lung Cancer: Current Knowledge and Future Directions, J Clin Oncol. avr, vol.23, issue.11, pp.2556-68, 2005.

N. Girard, Tumeurs intra-thoraciques: mutations oncogéniques et problématiques cliniques: prédisposition génétique au cancer broncho-pulmonaire chez le patient non-fumeur: hétérogénéité inter-et intra-tumorale des cancers broncho-pulmonaires: étude génomique intégrative des tumeurs épithéliales du thymus

. Médecine-humaine and . Pathologie, Français. NNT : 2011LYO10142. tel-00926538, p.97, 2011.

W. Pao and V. A. Miller, Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non-Small-Cell Lung Cancer: Current Knowledge and Future Directions, J Clin Oncol, vol.23, issue.11, pp.2556-68, 2005.

V. A. Miller, M. G. Kris, N. Shah, J. Patel, C. Azzoli et al., Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced nonsmall-cell lung cancer, J Clin Oncol Off J Am Soc Clin Oncol. 15 mars, vol.22, issue.6, pp.1103-1112, 2004.

J. G. Paez, P. A. Jänne, J. C. Lee, S. Tracy, H. Greulich et al., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science. 4 juin, vol.304, issue.5676, pp.1497-500, 2004.

W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi et al., EGF receptor gene mutations are common in lung cancers from « never smokers » and are associated with sensitivity of tumors to gefitinib and erlotinib, Proc Natl Acad Sci, vol.101, issue.36, pp.13306-13317, 2004.

H. Shigematsu and A. F. Gazdar, Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers, Int J Cancer, vol.118, issue.2, pp.257-62, 2006.

S. Murray, I. J. Dahabreh, H. Linardou, M. Manoloukos, D. Bafaloukos et al., Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung Cancer: An Analytical Database, J Thorac Oncol. 1 août, vol.3, issue.8, pp.832-841, 2008.

J. Cadranel, G. Zalcman, and L. Sequist, Genetic profiling and epidermal growth factor receptordirected therapy in nonsmall cell lung cancer, Eur Respir J. 1 janv, vol.37, issue.1, pp.183-93, 2011.

M. Beau-faller, N. Prim, A. Ruppert, N. Lacave, R. Lacroix et al., Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network, Ann Oncol. janv, vol.25, issue.1, pp.126-157, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02181347

J. Wu, S. Wu, Y. Gow, C. Chang, Y. Yu et al., Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response, Clin Cancer Res. 1 août, vol.14, issue.15, pp.4877-82, 2008.

W. Pao and N. Girard, New driver mutations in non-small-cell lung cancer, Lancet Oncol. 1 févr, vol.12, issue.2, pp.175-80, 2011.

T. Mitsudomi and Y. Yatabe, Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer, Cancer Sci. 1 déc, vol.98, issue.12, pp.1817-1841, 2007.

A. Pallis, E. Briasoulis, H. Linardou, C. Papadimitriou, D. Bafaloukos et al., Mechanisms of Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-Small-Cell Lung Cancer: Clinical and Molecular Considerations, Curr Med Chem. 31 mars, vol.18, issue.11, pp.1613-1641, 2011.

S. V. Sharma, D. W. Bell, J. Settleman, and D. A. Haber, Epidermal growth factor receptor mutations in lung cancer, Nat Rev Cancer. mars, vol.7, issue.3, pp.169-81, 2007.

M. G. Denis, A. Vallée, and S. Théoleyre, EGFR T790M resistance mutation in non small-cell lung carcinoma, Clin Chim Acta. avr, vol.444, pp.81-86, 2015.

N. Girard, E. Lou, C. G. Azzoli, R. Reddy, M. Robson et al., Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report, Clin Cancer Res Off J Am Assoc Cancer Res. 15 janv, vol.16, issue.2, pp.755-63, 2010.

D. W. Bell, I. Gore, R. A. Okimoto, N. Godin-heymann, R. Sordella et al., Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR, Nat Genet. déc, vol.37, issue.12, pp.1315-1321, 2005.

G. R. Oxnard, V. A. Miller, M. E. Robson, C. G. Azzoli, W. Pao et al., Brief report: Screening for germline EGFR T790M mutations through lung cancer genotyping, J Thorac Oncol. juin, vol.7, issue.6, pp.1049-52, 2012.

M. Inukai, S. Toyooka, S. Ito, H. Asano, S. Ichihara et al., Presence of Epidermal Growth Factor Receptor Gene T790M Mutation as a Minor Clone in Non-Small Cell Lung Cancer, Cancer Res. 15 août, vol.66, issue.16, pp.7854-7862, 2006.

E. Castellanos, E. Feld, and L. Horn, Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer, J Thorac Oncol. 1 avr, vol.12, issue.4, pp.612-635, 2017.

T. S. Mok, Y. Wu, S. Thongprasert, C. Yang, D. Chu et al., Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med. 3 sept, vol.361, issue.10, pp.947-57, 2009.

R. Rosell, T. Moran, C. Queralt, R. Porta, F. Cardenal et al., Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer, N Engl J Med. 3 sept, vol.361, issue.10, pp.958-67, 2009.

G. R. Oxnard, M. E. Arcila, C. S. Sima, G. J. Riely, J. Chmielecki et al., Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation, Clin Cancer Res. 15 mars, vol.17, issue.6, pp.1616-1638, 2011.

M. E. Arcila, G. R. Oxnard, K. Nafa, G. J. Riely, S. B. Solomon et al., Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay, Clin Cancer Res. 1 mars, vol.17, issue.5, pp.1169-80, 2011.

T. S. Mok, Y. Wu, M. Ahn, M. C. Garassino, H. R. Kim et al., Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer, N Engl J Med. 6 déc, vol.376, issue.7, pp.629-669, 2016.

H. A. Yu, M. E. Arcila, N. Rekhtman, C. S. Sima, M. F. Zakowski et al., Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers, Clin Cancer Res. 15 avr, vol.19, issue.8, pp.2240-2247, 2013.

S. W. Morris, M. N. Kirstein, M. B. Valentine, K. G. Dittmer, D. N. Shapiro et al., Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 4 mars, vol.263, pp.1281-1285, 1994.

M. Soda, Y. L. Choi, M. Enomoto, S. Takada, Y. Yamashita et al., Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature. août, vol.448, issue.7153, pp.561-567, 2007.

P. L. Chia, P. Mitchell, A. Dobrovic, and T. John, Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors, Clin Epidemiol, vol.6, pp.423-455, 2014.

J. P. Koivunen, C. Mermel, K. Zejnullahu, C. Murphy, E. Lifshits et al., EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer, Clin Cancer Res Off J Am Assoc Cancer Res. 1 juill, vol.14, issue.13, pp.4275-83, 2008.

L. Horn and W. Pao, EML4-ALK: honing in on a new target in non-small-cell lung cancer, J Clin Oncol Off J Am Soc Clin Oncol. 10 sept, vol.27, issue.26, pp.4232-4237, 2009.

M. P. Martelli, G. Sozzi, L. Hernandez, V. Pettirossi, A. Navarro et al., EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues, Am J Pathol. 1 févr, vol.174, issue.2, pp.661-70, 2009.

K. Inamura, K. Takeuchi, Y. Togashi, S. Hatano, H. Ninomiya et al., EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset, Mod Pathol. avr, vol.22, issue.4, pp.508-523, 2009.

D. Wong, E. Leung, K. So, I. Tam, A. Sihoe et al., The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS, Cancer. 15 avr, vol.115, issue.8, pp.1723-1756, 2009.

I. Zhang, N. G. Zaorsky, J. D. Palmer, R. Mehra, and B. Lu, Targeting brain metastases in ALKrearranged non-small-cell lung cancer, Lancet Oncol, vol.16, issue.13, pp.510-521, 2015.

R. C. Doebele, A. B. Pilling, D. L. Aisner, T. G. Kutateladze, A. T. Le et al., Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer, Clin Cancer Res. 1 mars, vol.18, issue.5, pp.1472-82, 2012.

L. P. Chin, R. A. Soo, R. Soong, S. Ou, and . Hi, Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non-Small-Cell Lung Cancer, J Thorac Oncol, vol.7, issue.11, pp.1625-1655, 2012.

K. Takeuchi, M. Soda, Y. Togashi, R. Suzuki, S. Sakata et al., ROS1 and ALK fusions in lung cancer, Nat Med. mars, vol.18, issue.3, pp.378-81, 2012.

K. Bergethon, A. T. Shaw, I. Ou, S. Katayama, R. Lovly et al., ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers, J Clin Oncol. 3 janv, vol.30, issue.8, pp.863-70, 2012.

Q. Zhu, P. Zhan, X. Zhang, T. Lv, and Y. Song, Clinicopathologic characteristics of patients with ROS1 fusion gene in non-small cell lung cancer: a meta-analysis, Transl Lung Cancer Res. juin, vol.4, issue.3, pp.300-309, 2015.

A. T. Shaw, S. Ou, Y. Bang, D. R. Camidge, B. J. Solomon et al., Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer, N Engl J Med, vol.371, issue.21, pp.1963-71, 2014.

J. Mazières, G. Zalcman, L. Crinò, P. Biondani, F. Barlesi et al., Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort, J Clin Oncol. 9 févr, vol.33, issue.9, pp.992-1001, 2015.

D. Moro-sibilot, L. Faivre, G. Zalcman, M. Pérol, F. Barlesi et al., Crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Preliminary results of the ACSé phase II trial, J Clin Oncol. 20 mai, vol.33, pp.8065-8065, 2015.

J. F. Gainor, D. Tseng, S. Yoda, I. Dagogo-jack, L. Friboulet et al., Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer, JCO Precis Oncol, 2017.

C. E. Mccoach, A. T. Le, K. Gowan, K. Jones, L. Schubert et al., Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer, Clin Cancer Res. 15 juill, vol.24, issue.14, pp.3334-3381, 2018.

D. T. Leicht, V. Balan, A. Kaplun, V. Singh-gupta, L. Kaplun et al., Raf Kinases: Function, Regulation and Role in Human Cancer, Biochim Biophys Acta. août, vol.1773, issue.8, pp.1196-212, 2007.

H. Davies, G. R. Bignell, C. Cox, P. Stephens, S. Edkins et al., Mutations of the BRAF gene in human cancer, Nature. juin, vol.417, issue.6892, p.949, 2002.

K. Naoki, T. H. Chen, W. G. Richards, D. J. Sugarbaker, and M. Meyerson, Missense mutations of the BRAF gene in human lung adenocarcinoma, Cancer Res. 1 déc, vol.62, issue.23, pp.7001-7004, 2002.

H. Sasaki, O. Kawano, and K. Endo, Uncommon V599E BRAF Mutations in Japanese Patients with Lung Cancer, J Surg Res, vol.133, issue.2, pp.203-209

L. Ding, G. Getz, D. A. Wheeler, E. R. Mardis, M. D. Mclellan et al., Somatic mutations affect key pathways in lung adenocarcinoma, Nature, vol.455, issue.7216, pp.1069-75, 2008.

W. Pao, T. Y. Wang, G. J. Riely, V. A. Miller, Q. Pan et al., KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib, PLoS Med. janv, vol.2, issue.1, p.17, 2005.

M. Fakih, B. O'neil, T. J. Price, G. S. Falchook, J. Desai et al., Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors, J Clin Oncol. 20 mai, vol.37, pp.3003-3003, 2019.

L. Coussens, T. L. Yang-feng, Y. C. Liao, C. E. Gray, A. Mcgrath et al., Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene, Science. 6 déc, vol.230, issue.4730, pp.1132-1141, 1985.

P. Stephens, C. Hunter, G. Bignell, S. Edkins, H. Davies et al., Lung cancer: intragenic ERBB2 kinase mutations in tumours, Nature, vol.431, issue.7008, pp.525-531, 2004.

K. Tomizawa, K. Suda, R. Onozato, T. Kosaka, H. Endoh et al., Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers, Lung Cancer, vol.74, issue.1, pp.139-183, 2011.

M. E. Arcila, J. E. Chaft, K. Nafa, S. Roy-chowdhuri, C. Lau et al., clinicopathologic associations and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas, Clin Cancer Res Off J Am Assoc Cancer Res. 15 sept, vol.18, issue.18, pp.4910-4918, 2012.

H. Shigematsu, T. Takahashi, M. Nomura, K. Majmudar, M. Suzuki et al., Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas, Cancer Res. 1 mars, vol.65, issue.5, pp.1642-1648, 2005.

. Mazières, Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives, J Clin Oncol. 1 juin, vol.31, issue.16, pp.1997-2003, 2013.

. Intergroupe-francophone-de-cancerologie-thoracique, Phase II trial of trastuzumab in combination with pertuzumab in pretreated patients with non-small cell lung cancer (NSCLC) harboring a Her2 mutation and receiving docetaxel R2D2 trial (Her2-positive lung cancer treated with Dedicated Drug). IFCT-1703 R2D2

M. Sattler, M. M. Reddy, R. Hasina, T. Gangadhar, and R. Salgia, The role of the c-Met pathway in lung cancer and the potential for targeted therapy, Ther Adv Med Oncol. juill, vol.3, issue.4, pp.171-84, 2011.

A. B. Cortot, Z. Kherrouche, C. Descarpentries, M. Wislez, S. Baldacci et al., Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers, JNCI J Natl Cancer Inst. 1 mai, vol.109, issue.5, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02413937

W. Sterlacci, M. Fiegl, M. Gugger, L. Bubendorf, S. Savic et al., MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLC, Virchows Arch. 1 juill, vol.471, issue.1, pp.49-55, 2017.

G. M. Frampton, S. M. Ali, M. Rosenzweig, J. Chmielecki, X. Lu et al., Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors, Cancer Discov. 1 août, vol.5, issue.8, pp.850-859, 2015.

V. Fallet, R. Saffroy, N. Girard, J. Mazieres, S. Lantuejoul et al., High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta TM Panel: exploring therapeutic targets, Ann Oncol. 1 août, vol.26, issue.8, pp.1748-53, 2015.

R. Saffroy, V. Fallet, N. Girard, J. Mazieres, D. M. Sibilot et al., MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung, Oncotarget. 21 mars, vol.8, issue.26, pp.42428-42465, 2017.

J. H. Tong, S. F. Yeung, A. Chan, L. Y. Chung, S. L. Chau et al., MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis, Clin Cancer Res. 15 juin, vol.22, issue.12, pp.3048-56, 2016.

C. Jimenez, D. R. Jones, P. Rodríguez-viciana, A. Gonzalez-garcía, L. E. Wennström et al., Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase, EMBO J. 2 févr, vol.17, issue.3, pp.743-53, 1998.

Y. Samuels, Z. Wang, and A. Badelli, High Frequency of Mutations of the PIK3CA Gene in Human Cancers | Science, Science. avr, vol.304, issue.5670, p.554, 2004.

O. Kawano, H. Sasaki, K. Endo, E. Suzuki, H. Haneda et al., PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer, vol.54, pp.209-224, 2006.

H. Yamamoto, Y. Yatabe, and S. Toyooka, Inherited lung cancer syndromes targeting never smokers, Transl Lung Cancer Res. 21 juin, vol.7, issue.4, pp.498-504, 2018.

K. Okudela, M. Suzuki, S. Kageyama, T. Bunai, K. Nagura et al., PIK3CA mutation and amplification in human lung cancer, Pathol Int, vol.57, issue.10, pp.664-71, 2007.

J. E. Chaft, M. E. Arcila, P. K. Paik, C. Lau, G. J. Riely et al., Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma -rationale for comprehensive mutation profiling, Mol Cancer Ther. févr, vol.11, issue.2, pp.485-91, 2012.

O. Kawano, H. Sasaki, K. Okuda, H. Yukiue, T. Yokoyama et al., PIK3CA gene amplification in Japanese non-small cell lung cancer. Lung Cancer, vol.58, pp.159-60, 2007.

B. Angulo, A. Suarez-gauthier, F. Lopez-rios, P. P. Medina, E. Conde et al., Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification, J Pathol, vol.214, issue.3, pp.347-56, 2008.

N. Guibert, F. Barlesi, R. Descourt, H. Léna, B. Besse et al., Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France, J Thorac Oncol. juin, vol.12, issue.6, pp.963-73, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01699240

S. Li, L. Li, Y. Zhu, C. Huang, Y. Qin et al., Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts, Br J Cancer. mai, vol.110, issue.11, pp.2812-2832, 2014.

K. Töpfer, S. Kempe, N. Müller, M. Schmitz, M. Bachmann et al., Tumor Evasion from T Cell Surveillance, BioMed Res Int, p.918471, 2011.

D. M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer. avr, vol.12, issue.4, pp.252-64, 2012.

K. C. Ohaegbulam, A. Assal, E. Lazar-molnar, Y. Yao, and X. Zang, Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway, Trends Mol Med. 1 janv, vol.21, issue.1, pp.24-33, 2015.

M. Reck, D. Rodríguez-abreu, A. G. Robinson, R. Hui, T. Cs?szi et al., Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N Engl J Med, vol.375, issue.19, pp.1823-1856, 2016.

H. Borghaei, L. Paz-ares, L. Horn, D. R. Spigel, M. Steins et al., Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, issue.17, pp.1627-1666, 2015.

R. S. Herbst, P. Baas, D. Kim, E. Felip, J. L. Pérez-gracia et al., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet, vol.9, pp.1540-50, 2016.

A. Jeanson, P. Tomasini, M. Souquet-bressand, N. Brandone, M. Boucekine et al., Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC), J Thorac Oncol. 1 juin, vol.14, issue.6, pp.1095-101, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02104417

J. Mazieres, A. Drilon, A. Lusque, L. Mhanna, A. B. Cortot et al., Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry, Ann Oncol. 1 août, vol.30, issue.8, pp.1321-1329, 2019.

S. J. Antonia, A. Villegas, D. Daniel, D. Vicente, S. Murakami et al., Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer, N Engl J Med, vol.377, issue.20, pp.1919-1948, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01753457

M. Maemondo, A. Inoue, K. Kobayashi, S. Sugawara, S. Oizumi et al., Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N Engl J Med. 24 juin, vol.362, issue.25, pp.2380-2388, 2010.

T. Mitsudomi, S. Morita, Y. Yatabe, S. Negoro, I. Okamoto et al., Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, Lancet Oncol. févr, vol.11, issue.2, pp.121-129, 2010.

C. K. Lee, Y. Wu, P. N. Ding, S. J. Lord, A. Inoue et al., Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis, J Clin Oncol. 20 avr, vol.33, issue.17, pp.1958-65, 2015.

J. Soria, Y. Ohe, J. Vansteenkiste, T. Reungwetwattana, B. Chewaskulyong et al., Osimertinib in Untreated EGFR -Mutated Advanced Non-Small-Cell Lung Cancer, N Engl J Med. 11 janv, vol.378, issue.2, pp.113-138, 2018.

B. J. Solomon, T. Mok, D. Kim, Y. Wu, K. Nakagawa et al., First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N Engl J Med. 4 déc, vol.371, issue.23, pp.2167-77, 2014.

A. T. Shaw, D. Kim, R. Mehra, D. Tan, E. Felip et al., Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer. 26 mars, vol.370, pp.1189-97, 2014.

J. Soria, D. Tan, R. Chiari, Y. Wu, L. Paz-ares et al., First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. The Lancet. 4 mars, vol.389, pp.917-946, 2017.

S. Peters, D. R. Camidge, A. T. Shaw, S. Gadgeel, J. S. Ahn et al., Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer, N Engl J Med, vol.31, issue.9, pp.829-867, 2017.

T. Seto, M. Nishio, T. Hida, H. Nokihara, M. Morise et al., Final PFS analysis and safety data from the phase III J-ALEX study of alectinib (ALC) vs. crizotinib (CRZ) in ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC), J Clin Oncol. 20 mai, vol.37, pp.9092-9092, 2019.

D. Kim, M. Tiseo, M. Ahn, K. L. Reckamp, K. H. Hansen et al., Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial, J Clin Oncol Off J Am Soc Clin Oncol. 1 août, vol.35, issue.22, pp.2490-2498, 2017.

A. T. Shaw, E. Felip, T. M. Bauer, B. Besse, A. Navarro et al., Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial, Lancet Oncol, vol.18, issue.12, pp.1590-1599, 2017.

D. Planchard, T. M. Kim, J. Mazieres, E. Quoix, G. Riely et al., Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial, Lancet Oncol, vol.17, issue.5, pp.642-50, 2016.

D. Planchard, B. Besse, H. Groen, P. Souquet, E. Quoix et al., Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic nonsmall cell lung cancer: an open-label, multicentre phase 2 trial, Lancet Oncol. juill, vol.17, issue.7, pp.984-93, 2016.

D. Planchard, E. F. Smit, H. Groen, J. Mazieres, B. Besse et al., Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic nonsmall-cell lung cancer: an open-label, phase 2 trial, Lancet Oncol, vol.18, issue.10, pp.1307-1323, 2017.

. Has, . Tafinlar, and . Avis, Commission de transparence, 2018.

J. Wolf, T. Seto, J. Han, N. Reguart, E. B. Garon et al., Capmatinib (INC280) in MET?ex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study, J Clin Oncol. 20 mai, vol.37, pp.9004-9004, 2019.

G. Myrdal, M. Lambe, G. Hillerdal, K. Lamberg, T. Agustsson et al., Effect of delays on prognosis in patients with non-small cell lung cancer, Thorax. 1 janv, vol.59, issue.1, pp.45-54, 2004.

F. J. Gonzalez-barcala, J. A. Falagan, J. M. Garcia-prim, L. Valdes, J. M. Carreira et al., Timeliness of care and prognosis in patients with lung cancer, Ir J Med Sci, vol.183, issue.3, pp.383-90, 1971.

M. M. Jacobsen, S. C. Silverstein, M. Quinn, L. B. Waterston, C. A. Thomas et al., Timeliness of access to lung cancer diagnosis and treatment: A scoping literature review. Lung Cancer, vol.112, pp.156-64, 2017.

J. K. Olsson, E. M. Schultz, and M. K. Gould, Timeliness of care in patients with lung cancer: a systematic review, Thorax. 1 sept, vol.64, issue.9, pp.749-56, 2009.

R. Diaconescu, C. Lafond, and R. Whittom, Treatment Delays in Non-small Cell Lung Cancer and Their Prognostic Implications, J Thorac Oncol. 1 juill, vol.6, issue.7, pp.1254-1263, 2011.

N. F. Kanarek, C. M. Hooker, L. Mathieu, H. Tsai, C. M. Rudin et al., Survival After Community Diagnosis of Early-stage Non-small Cell Lung Cancer, Am J Med. 1 mai, vol.127, issue.5, pp.443-452, 2014.

N. Mohammed, L. L. Kestin, I. S. Grills, M. Battu, D. L. Fitch et al., Rapid Disease Progression With Delay in Treatment of Non-Small-Cell Lung Cancer, Int J Radiat Oncol. 1 févr, vol.79, issue.2, pp.466-72, 2011.

T. Risberg, S. W. Sørbye, J. Norum, and E. A. Wist, Diagnostic delay causes more psychological distress in female than in male cancer patients, Anticancer Res. avr, vol.16, issue.2, pp.995-1004, 1996.

, Étude sur les délais de prise en charge des cancers du sein et du poumon

J. Ferlay, M. Ervik, F. Lam, and M. Colombet, Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods, Int J Cancer, vol.144, issue.8, pp.1941-1953, 2018.

C. Allemani, T. Matsuda, D. Carlo, V. Harewood, R. Matz et al., Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries, Lancet. 17 mars, vol.391, pp.1023-75, 2018.

C. Allemani, H. Weir, R. Harewood, D. Spika, and X. Wang, Global surveillance of cancer survival 1995-2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2), Lancet. mars, vol.385, issue.9972, pp.977-1010, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01912088

J. Lortet-tieulent, I. Soerjomataram, J. Ferlay, M. Rutherford, E. Weiderpass et al., International trends in lung cancer incidence by histological subtype: Adenocarcinoma stabilizing in men but still increasing in women, Lung Cancer. 1 avr, vol.84, issue.1, pp.13-22, 2014.

S. Dearden, J. Stevens, Y. Wu, and D. Blowers, Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap), Ann Oncol. sept, vol.24, issue.9, pp.2371-2377, 2013.

A. Chougule, K. Prabhash, V. Noronha, A. Joshi, A. Thavamani et al., Frequency of EGFR Mutations in 907 Lung Adenocarcioma Patients of Indian Ethnicity, PLoS One, vol.8, issue.10, p.76164, 2013.

A. Vallée, C. Sagan, L. Loupp, A. Bach, K. Dejoie et al., Detection of EGFR gene mutations in non-small cell lung cancer: Lessons from a single-institution routine analysis of 1,403 tumor samples, Int J Oncol, vol.07, issue.4, pp.1045-51, 2013.

Å. Helland, H. M. Skaug, L. Kleinberg, M. L. Iversen, A. K. Rud et al., EGFR Gene Alterations in a Norwegian Cohort of Lung Cancer Patients Selected for Surgery, J Thorac Oncol. 1 mai, vol.6, issue.5, pp.947-50, 2011.

K. Hlinkova, P. Babal, P. Berzinec, I. Majer, Z. Mikle-barathova et al., Evaluation of 2-Year Experience With EGFR Mutation Analysis of Small Diagnostic Samples, Diagn Mol Pathol. 1 juin, vol.22, issue.2, pp.70-75, 2013.

A. Midha, S. Dearden, and R. Mccormack, EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII), Am J Cancer Res, vol.5, issue.9, pp.2892-2911, 2015.

G. Defossez, L. Guyader-peyrou, S. Uhry, A. Grosclaude, and P. , Estimations nationales de l'incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018. Étude à partir des registres des cancers du réseau Francim. Résultats préliminaires. Rapport. Saint-Maurice (Fra) : Santé publique France, 2019.

M. Bardot and E. Chirpaz, Les Cancers à La Réunion

F. Martin, Le cancer broncho-pulmonaire dans le département de La Réunion: caractéristiques cliniques et démographiques

F. Blinder-foucard, A. Belot, and P. Delafosse, Estimation nationale de l'incidence et de la mortalité par cancer en France entre 1980 et 2012. Etude à partir des registres des cancers du réseau Francim. Partie 1. Tumeurs solides

D. Debieuvre, C. Locher, A. Neidhardt, F. Goupil, B. Lemaire et al., Évolution en 10ans du cancer bronchique non à petites cellules en fonction du sexe. Résultats de l'étude KBP-2010-CPHG du Collège des pneumologues des hôpitaux généraux, Rev Mal Respir, vol.31, issue.9, pp.805-821, 2014.

S. A. Khuder, Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis, Lung Cancer. 1 mars, vol.31, issue.2, pp.139-187, 2001.

D. M. Burns, C. M. Anderson, and N. Gray, Do changes in cigarette design influence the rise in adenocarcinoma of the lung?, Cancer Causes Control. 1 janv, vol.22, issue.1, pp.13-22, 2011.

J. Malhotra, M. Malvezzi, E. Negri, L. Vecchia, and C. , Risk factors for lung cancer worldwide, Eur Respir J, vol.48, issue.3, pp.889-902, 2016.

R. Doll and A. B. Hill, Smoking and Carcinoma of the Lung, Br Med J. 30 sept, vol.2, issue.4682, pp.739-787, 1950.

F. Beck, J. Richard, T. Gauduchon, and S. Spilka, Les usages de drogues dans les DOM en 2014 chez les adolescents et les adultes -Tendances 111 -juillet 2016 2 -OFDT

D. Sur,

R. Andler, J. Richard, and . Nguyen-thanh, Baromètre santé DOM 2014. Tabagisme et usage d'e-cigarette, vol.14, 2014.

A. Pasquereau, R. Andler, R. Guignard, J. Richard, P. Ardwison et al., International Agency for Research on Cancer. Agents classified by the IARC monographs. volumes 1-122, Premiers résultats du baromètre santé, vol.168, 2017.

S. Darby, D. Hill, H. Deo, A. Auvinen, J. M. Barros-dios et al., Residential radon and lung cancer-detailed results of a collaborative analysis of individual data on 7148 persons with lung cancer and 14 208 persons without lung cancer from 13 epidemiologic studies in Europe, Scand J Work Environ Health, vol.32, issue.1, pp.1-84, 2006.

N. Leduc, C. Ahomadegbe, M. Agossou, A. Aline-fardin, L. Mahjoubi et al., Incidence of Lung Adenocarcinoma Biomarker in a Caribbean and African Caribbean Population, J Thorac Oncol. 1 mai, vol.11, issue.5, pp.769-73, 2016.

J. Lissowska, A. Bardin-mikolajczak, T. Fletcher, and D. Zaridze, Lung Cancer and Indoor Pollution from Heating and Cooking with Solid Fuels, Am J Epidemiol. 15 août, vol.162, issue.4, pp.326-359, 2005.

I. Yu, Y. Chiu, J. Au, T. Wong, and J. Tang, Dose-Response Relationship between Cooking Fumes Exposures and Lung Cancer among Chinese Nonsmoking Women, Cancer Res. 1 mai, vol.66, issue.9, pp.4961-4968, 2006.

S. Aldington, M. Harwood, B. Cox, M. Weatherall, L. Beckert et al., Cannabis use and risk of lung cancer: a case-control study, Eur Respir J. 1 févr, vol.31, issue.2, pp.280-286, 2008.

Y. Huang, Z. Zhang, D. P. Tashkin, B. Feng, K. Straif et al., An epidemiologic review of marijuana and cancer: an update, Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. janv, vol.24, issue.1, pp.15-31, 2015.

S. Sun, J. Schiller, and A. Gazdar, Lung cancer in never smokers -a different disease, Nat Rev Cancer, vol.7, issue.10, pp.778-90, 2007.

J. Subramanian and R. Govindan, Lung Cancer in Never Smokers: A Review, J Clin Oncol. 10 févr, vol.25, issue.5, pp.561-70, 2007.

S. Couraud, G. Zalcman, B. Milleron, F. Morin, and P. Souquet, Lung cancer in never smokers -A review, Eur J Cancer. 1 juin, vol.48, issue.9, pp.1299-311, 2012.

J. E. Enstrom, Rising lung cancer mortality among nonsmokers, J Natl Cancer Inst. avr, vol.62, issue.4, pp.755-60, 1979.

P. Boffetta, B. Järvholm, P. Brennan, and O. Nyrén, Incidence of lung cancer in a large cohort of non-smoking men from Sweden, Int J Cancer, vol.94, issue.4, pp.591-594, 2001.

F. Forastiere, C. A. Perucci, M. Arcà, and O. Axelson, Indirect estimates of lung cancer death rates in Italy not attributable to active smoking. Epidemiol Camb Mass, vol.4, pp.502-512, 1993.

H. A. Wakelee, E. T. Chang, S. L. Gomez, T. H. Keegan, D. Feskanich et al., Lung Cancer Incidence in Never Smokers, J Clin Oncol. 10 févr, vol.25, issue.5, pp.472-480, 2007.

M. Parkin, F. Bray, J. Ferlay, and P. Pisani, Global Cancer Statisticsy, CA Cancer J Clin, vol.385, issue.9972, pp.977-1010, 2014.

J. Ferlay, H. Shin, F. Bray, D. Forman, C. Mathers et al., Estimates of worldwide burden of cancer in 2008: GLOBOCAN, Int J Cancer. 15 déc, vol.127, issue.12, pp.2893-917, 2008.

M. J. Thun, L. M. Hannan, L. L. Adams-campbell, P. Boffetta, J. E. Buring et al., Lung Cancer Occurrence in Never-Smokers: An Analysis of 13 Cohorts and 22 Cancer Registry Studies, PLOS Med. 9 sept, vol.5, issue.9, p.185, 2008.

C. Toh, F. Gao, W. Lim, S. Leong, K. Fong et al., Never-Smokers With Lung Cancer: Epidemiologic Evidence of a Distinct Disease Entity, J Clin Oncol. 20 mai, vol.24, issue.15, pp.2245-51, 2006.

T. Yano, N. Miura, T. Takenaka, A. Haro, H. Okazaki et al., Never-smoking nonsmall cell lung cancer as a separate entity, Cancer, vol.113, issue.5, pp.1012-1020, 2008.

R. Govindan, Lung cancer in never smokers: a new hot area of research, Lancet Oncol. 1 avr, vol.11, issue.4, pp.304-309, 2010.

G. Scagliotti, M. Longo, and S. Novello, Nonsmall cell lung cancer in never smokers, Curr Opin Oncol. 1 mars, vol.21, issue.2, pp.99-104, 2009.

E. Radzikowska, P. G?az, and K. Roszkowski, Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases, Ann Oncol. 1 juill, vol.13, issue.7, pp.1087-93, 2002.

C. Toh, W. Ong, W. Lim, D. Tan, Q. Ng et al., A Decade of Never-smokers Among Lung Cancer Patients-Increasing Trend and Improved Survival, Clin Lung Cancer. 1 sept, vol.19, issue.5, pp.539-50, 2018.

L. C. Koo and J. Ho, Worldwide Epidemiological Patterns of Lung Cancer in Nonsmokers, Int J Epidemiol. 1 janv, vol.19, issue.Supplement_1, pp.14-23, 1990.

Y. Janjigian, K. Mcdonnell, M. Kris, R. Shen, C. Sima et al., Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer, Cancer. 1 févr, vol.116, issue.3, pp.670-675, 2010.

L. T. Nordquist, G. R. Simon, A. Cantor, W. M. Alberts, and G. Bepler, Improved Survival in Never-Smokers vs Current Smokers With Primary Adenocarcinoma of the Lung, Chest. 1 août, vol.126, issue.2, pp.347-51, 2004.

P. Brennan, P. A. Buffler, P. Reynolds, A. H. Wu, H. E. Wichmann et al., Secondhand smoke exposure in adulthood and risk of lung cancer among never smokers: a pooled analysis of two large studies, Int J Cancer. mars, vol.109, issue.1, pp.125-156, 2004.

E. Fontham, P. Correa, P. Reynolds, A. Wu-williams, P. A. Buffler et al., Environmental Tobacco Smoke and Lung Cancer in Nonsmoking Women: A Multicenter Study, Jama. 8 juin, vol.271, issue.22, pp.1752-1761, 1994.

S. Darby, D. Hill, A. Auvinen, J. M. Barros-dios, H. Baysson et al., Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies, BMJ. 29 janv, vol.330, issue.7485, p.223, 2005.

D. Krewski, J. Lubin, J. Zielinski, M. Alavanja, V. Catalan et al., Residential Radon and Risk of Lung Cancer: A Combined Analysis of 7 North American Case-Control Studies, Epidemiology. 1 mars, vol.16, issue.2, pp.137-182, 2005.

J. Pairon, P. Andujar, M. Matrat, and J. Ameille,

, Rev Mal Respir, vol.25, issue.8, pp.3-18, 2008.

M. C. Turner, D. Krewski, C. A. Pope, Y. Chen, S. M. Gapstur et al., Long-term ambient fine particulate matter air pollution and lung cancer in a large cohort of never-smokers, Am J Respir Crit Care Med. 15 déc, vol.184, issue.12, pp.1374-81, 2011.

Y. W. Cheng, H. L. Chiou, G. T. Sheu, L. L. Hsieh, J. T. Chen et al., The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women, Cancer Res. 1 avr, vol.61, issue.7, pp.2799-803, 2001.

P. K. Paik, M. E. Arcila, M. Fara, C. S. Sima, V. A. Miller et al., Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations, J Clin Oncol. 11 avr, vol.29, issue.15, pp.2046-51, 2011.

M. Mounawar, A. Mukeria, F. L. Calvez, R. J. Hung, H. Renard et al., Patterns of EGFR, HER2, TP53, and KRAS Mutations of p14arf Expression in Non-Small Cell Lung Cancers in Relation to Smoking History, Cancer Res. 15 juin, vol.67, issue.12, pp.5667-72, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00173094

A. Matakidou, T. Eisen, H. Bridle, M. O'brien, R. Mutch et al., Case-control study of familial lung cancer risks in UK women, Int J Cancer, vol.116, issue.3, pp.445-50, 2005.

J. Lissowska, L. Foretova, J. D?bek, D. Zaridze, N. Szeszenia-dabrowska et al., Family history and lung cancer risk: international multicentre case-control study in Eastern and Central Europe and meta-analyses, Cancer Causes Control. 1 juill, vol.21, issue.7, pp.1091-104, 2010.

R. J. Hung, J. D. Mckay, V. Gaborieau, P. Boffetta, M. Hashibe et al., A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25, Nature. avr, vol.452, issue.7187, pp.633-640, 2008.
URL : https://hal.archives-ouvertes.fr/cea-00944415

M. Besbes and C. Betti, Tableaux de l'économie française

S. P. D'angelo, M. C. Pietanza, M. L. Johnson, G. J. Riely, V. A. Miller et al., Incidence of EGFR Exon 19 Deletions and L858R in Tumor Specimens From Men and Cigarette Smokers With Lung Adenocarcinomas, J Clin Oncol. 11 avr, vol.29, issue.15, pp.2066-70, 2011.

D. C. Doval, K. Prabhash, S. Patil, H. Chaturvedi, C. Goswami et al., Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung, OncoTargets Ther. 5 janv, vol.8, pp.117-140, 2015.

H. Tu, E. Ke, Y. Sun, Y. Yan, H. Zheng et al., A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer, Lung Cancer Amst Neth, vol.114, pp.96-102, 2017.

H. Yasuda, S. Kobayashi, and D. B. Costa, EGFR exon 20 insertion mutations in non-smallcell lung cancer: preclinical data and clinical implications, Lancet Oncol. janv, vol.13, issue.1, pp.23-31, 2012.

G. R. Oxnard, P. Lo, M. Nishino, S. Dahlberg, N. I. Lindeman et al., Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions, J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. févr, vol.8, issue.2, pp.179-84, 2013.

J. Wu, C. Yu, Y. Chang, Y. Shih, J. et al., Effectiveness of Tyrosine Kinase Inhibitors on "Uncommon" Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non-Small Cell Lung Cancer, Clin Cancer Res. 1 juin, vol.17, issue.11, pp.3812-3833, 2011.

N. Girard, C. S. Sima, D. M. Jackman, L. V. Sequist, H. Chen et al., Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma, Eur Respir J. 1 févr, vol.39, issue.2, pp.366-72, 2012.

X. Zhang, S. Zhang, X. Yang, J. Yang, Q. Zhou et al., Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression, Classification TNM, 8ème édition : T (9,13) Tableau 9 : Classification TNM, 8ème édition : N (9,13) Tableau 10 : Classification TNM, 8ème édition : M, vol.9, p.188, 2013.